{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:40:53Z","timestamp":1793731253257,"version":"4.6.1"},"reference-count":28,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,12,30]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>Valproate (VPA) is broad-spectrum antiepileptic drug. Several adverse reactions including hepatotoxicity, fetal risk and pancreatitis are well known and labelled as boxed warnings in the USA. One adverse reaction that is less well known but clinically significant for its severe morbidity is hyperammonemic encephalopathy. We present a case of woman with hyperammonemic encephalopathy following the initiation of VPA therapy; she had a favourable outcome with discontinuation of the drug and prompt treatment with lactulose and L-carnitine.<\/jats:p>","DOI":"10.1136\/bcr-2023-257144","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T12:25:19Z","timestamp":1707827119000},"page":"e257144","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Hyperammonemic encephalopathy induced by valproic acid"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-7985","authenticated-orcid":false,"given":"Qiuyu M","family":"Zhu","sequence":"first","affiliation":[{"name":"Internal Medicine, Kaiser Permanente Mid-Atlantic States, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitosh K","family":"Singh","sequence":"additional","affiliation":[{"name":"Internal Medicine, Kaiser Permanente Mid-Atlantic States, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huai-En Rachel","family":"Chang","sequence":"additional","affiliation":[{"name":"Internal Medicine, Kaiser Permanente Mid-Atlantic States, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep A","family":"Konka","sequence":"additional","affiliation":[{"name":"Hospital Medicine, Mid-Atlantic Permanente Medical Group, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"2025082622404703000_17.2.e257144.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00655.x","article-title":"Valproate-induced hyperammonemic encephalopathy","volume":"114","author":"Segura-Bruna","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"2025082622404703000_17.2.e257144.2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P135"},{"key":"2025082622404703000_17.2.e257144.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2006.05.007"},{"key":"2025082622404703000_17.2.e257144.4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/NRL.0000000000000166","article-title":"Valproate-induced Hyperammonemic Encephalopathy Presenting as Catatonia","volume":"23","author":"P\u00e9rez-Esparza","year":"2018","journal-title":"Neurologist"},{"key":"2025082622404703000_17.2.e257144.5","doi-asserted-by":"crossref","DOI":"10.1186\/s13256-020-2343-x","article-title":"Valproate-induced hyperammonemic encephalopathy: a case report","volume":"14","author":"Shah","year":"2020","journal-title":"J Med Case Rep"},{"key":"2025082622404703000_17.2.e257144.6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.psym.2017.02.003","article-title":"Valproate-Induced Hyperammonemic Encephalopathy in General Hospital Patients With One or More Psychiatric Disorders","volume":"58","author":"Lewis","year":"2017","journal-title":"Psychosomatics"},{"key":"2025082622404703000_17.2.e257144.7","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.164.7.1020"},{"key":"2025082622404703000_17.2.e257144.8","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110049"},{"key":"2025082622404703000_17.2.e257144.9","unstructured":"Ali R , Nagalli S . Treasure Island (FL) ineligible companies. disclosure: Shivaraj Nagalli declares no relevant financial relationships with ineligible companies. StatPearls, 2023."},{"key":"2025082622404703000_17.2.e257144.10","doi-asserted-by":"publisher","DOI":"10.1080\/15563650902752376"},{"key":"2025082622404703000_17.2.e257144.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.11.031"},{"key":"2025082622404703000_17.2.e257144.12","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000066","article-title":"Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy","volume":"93","author":"Tseng","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2025082622404703000_17.2.e257144.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.1.230"},{"key":"2025082622404703000_17.2.e257144.14","first-page":"128","article-title":"Valproic Acid and topiramate induced hyperammonemic encephalopathy in a patient with normal serum carnitine","volume":"18","author":"Blackford","year":"2013","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2025082622404703000_17.2.e257144.15","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0473-0"},{"key":"2025082622404703000_17.2.e257144.16","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-210727","article-title":"Reversible weakness and encephalopathy while on long-term valproate treatment due to carnitine deficiency","volume":"2015","author":"Al-sharefi","year":"2015","journal-title":"BMJ Case Rep"},{"key":"2025082622404703000_17.2.e257144.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2011.12.009"},{"key":"2025082622404703000_17.2.e257144.18","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/217269","article-title":"Hyperammonemia associated with valproic acid concentrations","volume":"2014","author":"V\u00e1zquez","year":"2014","journal-title":"Biomed Res Int"},{"key":"2025082622404703000_17.2.e257144.19","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/epi.12125","article-title":"Risk factors for hyperammonemia in pediatric patients with epilepsy","volume":"54","author":"Yamamoto","year":"2013","journal-title":"Epilepsia"},{"key":"2025082622404703000_17.2.e257144.20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s13760-021-01728-9","article-title":"Stupor in a catatonic patient due to an interaction between high-dose lorazepam and valproic acid: a case report","volume":"121","author":"de Neeling","year":"2021","journal-title":"Acta Neurol Belg"},{"key":"2025082622404703000_17.2.e257144.21","first-page":"281","article-title":"Stupor due to possible interaction between Lorazepam and valproic acid: report of two cases","volume":"23","author":"Uz","year":"2012","journal-title":"Turk Psikiyatri Derg"},{"key":"2025082622404703000_17.2.e257144.22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100324"},{"key":"2025082622404703000_17.2.e257144.23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4212\/cjhp.v70i3.1656","article-title":"Pharmacokinetic Interactions between Valproic Acid and Lorazepam (PIVOtAL Study): A Review of Site-Specific Practices","volume":"70","author":"Tang","year":"2017","journal-title":"Can J Hosp Pharm"},{"key":"2025082622404703000_17.2.e257144.24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/JCP.0000000000001659","article-title":"Valproate-Associated Hyperammonemic Encephalopathy: Clinical Correlates and Management Strategies in a Tertiary Care Center","volume":"43","author":"Vaidyanathan","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"2025082622404703000_17.2.e257144.25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27210"},{"key":"2025082622404703000_17.2.e257144.26","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2012.27.5.556"},{"key":"2025082622404703000_17.2.e257144.27","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1097\/MJT.0b013e3182a32e0e","article-title":"A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma","volume":"23","author":"Pilanc","year":"2016","journal-title":"Am J Ther"},{"key":"2025082622404703000_17.2.e257144.28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jocn.2013.04.033","article-title":"Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine","volume":"21","author":"Rigamonti","year":"2014","journal-title":"J Clin Neurosci"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-257144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T05:40:54Z","timestamp":1756273254000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-257144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,13]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/bcr-2023-257144"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-257144","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}